NEW YORK (GenomeWeb News) – Roche announced today that the Neuromuscular Disorder-Chip Consortium has selected Roche NimbleGen microarrays for its genetic research on neuromuscular disorders (NMDs).

The researchers will use custom-designed NimbleGen Human CGH 12x135K microarrays to look for NMD-related gene and exon level rearrangements, deletions, or insertions — particularly for NMDs such as Duchenne/Becker muscular dystrophies, limb girdle muscular dystrophies, congenital muscular dystrophies, hereditary motor-sensory neuropathies, and Charcot-Marie-Tooth neuropathies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.